经皮血管内治疗与开放非血管内治疗慢性肠系膜缺血的Meta分析
该系统评价与Meta分析纳入15项研究(血管内修复12326例 vs 开放手术6008例),比较慢性肠系膜缺血的早期与晚期结局。血管内修复与较低的30天死亡、心肌梗死、肺部及肾脏并发症风险相关,但与较低的5年总生存、较高的3年症状复发及5年再干预风险相关。
要点
- 血管内修复与较低的30天死亡风险相关(合并OR=0.58,95%CI 0.347-0.975,p=0.039)。
- 血管内修复与较低的30天心肌梗死、肺部及肾脏并发症风险相关。
- 血管内修复与较低的5年总生存及较高的3年症状复发、5年再干预风险相关。
核心结论
- 在慢性肠系膜缺血患者中,与开放手术相比,血管内修复与更优的早期结局和更差的晚期结局相关。
研究设计与样本
- 系统评价与Meta分析,遵循PRISMA指南,检索Pubmed、Embase、Scopus和Cochrane Library截至2024年4月在线发表的文献。
- 纳入比较血管内修复与开放手术治疗慢性肠系膜缺血早期和/或晚期结局的合格研究,共评估15项研究(发表于1995年至2024年),血管内修复12326例 vs 开放手术6008例。
主要发现
- 血管内修复与较低的30天死亡风险相关(合并OR=0.58,95%CI 0.347-0.975,p=0.039)。
- 血管内修复与较低的30天心肌梗死风险相关(合并OR=0.59,95%CI 0.351-0.989,p=0.045)。
- 血管内修复与较低的肺部并发症风险相关(合并OR=0.18,95%CI 0.075-0.426,p=0.0001)。
- 血管内修复与较低的30天肾脏并发症风险相关(合并OR=0.28,95%CI 0.146-0.553,p=.00002)。
- 血管内修复与较低的5年总生存相关(合并OR=0.414,95%CI 0.291-0.591,p<0.0001),并与较高的3年症状复发风险(合并OR=3.77,95%CI 2.314-6.142,p<0.0001)和较高的5年再干预风险(合并OR=2.40,95%CI 1.538-3.739,p=0.0001)相关。
临床怎么用
- 作者认为这些发现似乎进一步支持当前血管内优先的方法。
- 作者指出应考虑血管内修复很可能被选择用于临床状态较差的患者,开放手术可能更适合不适合血管内修复的较健康患者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Aim of this review is to compare pooled data on early and late outcomes between endovascular and open treatment for chronic mesenteric ischemia (CMI). MATERIALS AND METHODS: The present systematic review and meta-analysis was conducted under the PRISMA guidelines. The following databases were utilized: Pubmed, Embase, Scopus, and Cochrane Library. All eligible studies published online up to April 2024 were investigated. Eligible studies should compare early and/or late outcomes between endovascular repair (ER) and open surgery (OS) for CMI. Early outcomes included 30-day mortality, myocardial infarction (MI), pulmonary, gastrointestinal, and renal complications. Late outcomes included all-cause survival, symptom recurrence, and re-intervention. RESULTS: In total, 15 studies (published from 1995 to 2024) were evaluated (12,326 patients under ER versus 6008 patients under OS). Regarding 30-day outcomes, ER was associated with a lower 30-day mortality risk (pooled OR = 0.58; 95% CI [0.347-0.975]; p = 0.039), a lower 30-day MI risk (pooled OR = 0.59; 95% CI [0.351-0.989]; p=0.045), a lower pulmonary complications risk (pooled OR = 0.18; 95% CI [0.075-0.426]; p=0.0001), and a lower 30-day renal complications risk (pooled OR = 0.28; 95% CI [0.146-0.553]; p=.00002). Regarding late outcomes, ER was associated with a lower overall 5-year survival (pooled OR = 0.414; 95% CI [0.291-0.591]; p < 0.0001). ER was also associated with a higher 3-year symptom recurrence risk (pooled OR = 3.77; 95% CI [2.314-6.142]; p < 0.0001) and a higher 5-year re-intervention risk (pooled OR = 2.40; 95% CI [1.538-3.739]; p=0.0001). CONCLUSIONS: ER is associated with superior early outcomes and worse late outcomes compared to OS among patients treated for CMI.Clinical ImpactThis is the most updated meta-analysis comparing pooled data between percutaneous endovascular repair (ER) and open surgery (OS) for patients with chronic mesenteric ischemia. This review verifies the advantage of endovascular treatment regarding early outcomes. However, this benefit is lost in the long-term as far as mortality and re-interventions are concerned. These findings seem to further support the current endovascular-first approach. One should take into consideration that ER is probably selected for patients of worse clinical status. OS may be more suitable for fitter patients who are not candidates for ER.
引用
- Galyfos G, Chamzin A, Moisidis I, et al. Percutaneous Endovascular versus Open Non-Endovascular Treatment for Chronic Mesenteric Ischemia-A Meta-Analysis. J Endovasc Ther. 2025. PMID: 40257244. doi:10.1177/15266028251333627
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。